Novo Nordisk A/S Class B's other current liabilities is $45B.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (June 2026), NONOF shows a other current liabilities of $45B. That compares with $150B in the prior-year period — down 69.8% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, NONOF's other current liabilities is now $45B (was $150B) — a 69.8% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Novo Nordisk A/S Class B is outperforming or lagging.
Tracking NONOF's other current liabilities over time shows whether Novo Nordisk A/S Class B is scaling, shrinking, or reshaping that part of the business. The current reading is $45B That compares with $150B in the prior-year period — down 69.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this other current liabilities page, Stockcircle has Novo Nordisk A/S Class B's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other current liabilities (currently $45B) with ownership activity and broader fundamentals.
Novo Nordisk A/S Class B's other current liabilities is $45B; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.